Loading...
Publication
Cistatina B Urinária - Um Novo Biomarcador de Lesão Renal
| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 969.78 KB | Adobe PDF |
Advisor(s)
Abstract(s)
A lesão renal aguda (LRA) continua a ser uma das principais causas de morbilidade e mortalidade em
animais de companhia. A deteção precoce da lesão renal na fase subclínica permitiria aos médicos
veterinários intervir o mais rapidamente possível, a fim de preservar a saúde renal dos pacientes e
evitar danos irreversíveis ou o desenvolvimento de doença renal crónica (DRC). Os parâmetros
bioquímicos atuais, nomeadamente a creatinina sérica, a di-metilarginina simétrica e a densidade
urinária, não permitem identificar a lesão renal subclínica. Além disso, o sistema de classificação da
LRA proposto pela Sociedade Internacional de Interesse Renal baseia-se nos níveis de creatinina sérica,
mas estudos demonstraram que não é muito sensível.
O novo biomarcador Cistatina B urinária (uCysB) é uma proteína intracelular libertada na urina quando
os túbulos renais são danificados. A uCysB é, portanto, um marcador de lesão renal, sem ser
necessariamente acompanhada por uma perda da função renal.
É um parâmetro que demonstrou ter uma sensibilidade e especificidade próximas de 90% nas espécies
caninas e felinas domésticas para o diagnóstico de LRA. Vários estudos destacaram múltiplas
aplicações da uCysB, nomeadamente o diagnóstico precoce de lesões renais, bem como preditivo de
prognóstico e monitorização do tratamento da DRC.
A uCysB é o único marcador disponível na prática clínica em medicina veterinária como ferramenta de
diagnóstico de lesões renais. No entanto, continuam a decorrer estudos para implementar outros
marcadores de lesão.
Acute kidney injury (AKI) in domestic canine and feline species is still a major cause of morbidity and mortality. Early detection of subclinical kidney damage would enable veterinarians to intervene as quickly as possible to preserve patients' renal health and avoid irreversible damage or the development of chronic kidney disease (CKD) in the future. Current biochemical parameters - namely serum creatinine, symmetric di-methylarginine and urine density - do not allow subclinical kidney damage to be identified. In addition, the AKI classification system proposed by the International Renal Interest Society is currently based on the serum creatinine level but studies have shown that it is not very sensitive. The new biomarker urinary Cystatin B (uCysB) developed in thisreview article is an intracellular protein released in urine when renal tubules are damaged. As such, uCysB is a marker of renal injury and is not necessarily accompanied by a loss of renal function. This parameter has been shown to have a sensitivity and specificity of around 90% in domestic canine and feline species for the diagnosis of AKI. Various studies have highlighted the possible applications of uCysB: from diagnosing kidney damage to predicting prognosis and monitoring treatment of CKD. uCysB is the only marker available in clinical veterinary practice as a diagnostic tool for kidney injury. However, studies are ongoing to implement other markers of lesion.
Acute kidney injury (AKI) in domestic canine and feline species is still a major cause of morbidity and mortality. Early detection of subclinical kidney damage would enable veterinarians to intervene as quickly as possible to preserve patients' renal health and avoid irreversible damage or the development of chronic kidney disease (CKD) in the future. Current biochemical parameters - namely serum creatinine, symmetric di-methylarginine and urine density - do not allow subclinical kidney damage to be identified. In addition, the AKI classification system proposed by the International Renal Interest Society is currently based on the serum creatinine level but studies have shown that it is not very sensitive. The new biomarker urinary Cystatin B (uCysB) developed in thisreview article is an intracellular protein released in urine when renal tubules are damaged. As such, uCysB is a marker of renal injury and is not necessarily accompanied by a loss of renal function. This parameter has been shown to have a sensitivity and specificity of around 90% in domestic canine and feline species for the diagnosis of AKI. Various studies have highlighted the possible applications of uCysB: from diagnosing kidney damage to predicting prognosis and monitoring treatment of CKD. uCysB is the only marker available in clinical veterinary practice as a diagnostic tool for kidney injury. However, studies are ongoing to implement other markers of lesion.
Description
Keywords
Animais de companhia Biomarcador Cistatina B urinária Diagnóstico precoce Lesão renal aguda Prognóstico Acute kidney injury Biomarker Companion animals Early diagnosis Prognosis Urinary Cystatin B